Hand-foot syndrome variant in a dihydropyrimidine dehydrogenase - Deficient patient treated with capecitabine

Clinical Colorectal Cancer

Volumn 6, Issue 3, 2006, Pages 219-223

  Saif, Muhammad Wasif ^a,c   Elfiky, Aymen ^a   Diasio, Robert ^b  

^a YALE CANCER CENTER   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

5 fluorouracil; Chemotherapy; Neurotoxicity

Indexed keywords

CAPECITABINE; DERMATOLOGICAL AGENT; DIHYDROPYRIMIDINE DEHYDROGENASE; PYRIDOXINE; UDDERLY SMOOTH; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLISTER; CANCER ADJUVANT THERAPY; CASE REPORT; CLINICAL FEATURE; COMORBIDITY; DIAGNOSTIC VALUE; DIARRHEA; DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY; DISEASE SEVERITY; DRUG ERUPTION; DRUG WITHDRAWAL; ENZYME ACTIVITY; ENZYME DEFICIENCY; ERYTHEMA; HAND FOOT SYNDROME; HUMAN; HUMAN CELL; LABORATORY TEST; MALE; PAIN; PERIPHERAL BLOOD MONONUCLEAR CELL; RADIOENZYMATIC ASSAY; RECTUM CANCER; SKIN EXFOLIATION; SKIN SWELLING; TREATMENT OUTCOME;

EID: 33750192947     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2006.n.039     Document Type: Article

References (38)

1. Meta-Analysis Group in Cancer. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol 1998; 16:3537-3541.
2. Van Kuilenburg AB, Meinsma R, Zoetekouw L, et al. Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation. Int J Cancer 2002; 101:253-258.
3. Canellakis ES. Pyrimidine metabolism. I. Enzymatic pathways of uracil and thymine degradation. J Biol Chem 1956; 221:315-322.
4. Daher GC, Harris BE, Diasio RB. Metabolism of pyrimidine analogues and their nucleosides. Pharmacol Ther 1990; 48:189-222.
5. Diasio RB, Beavers TL, Carpenter JT. Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest 1988; 81:47-51.
6. Diasio RB, Johnson MR. Dihydropyrimidine dehydrogenase: its role in 5-fluorouracil clinical toxicity and tumor resistance. Clin Cancer Res 1999; 5:2672-2673.
7. Harris BE, Carpenter JT, Diasio RB. Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome. Cancer 1991; 68:499-501.
8. Morrison GB, Bastian A, Dela Rosa T, et al. Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing severe adverse reactions to 5-fluorouracil-based chemotherapy. Oncol Nurs Forum 1997; 24:83-88.
9. Ezzeldin H, Diasio R. Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration. Clin Colorectal Cancer 2004; 4:181-189.
10. Johnson MR, Wang K, Diasio RB. Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype. Clin Cancer Res 2002; 8:768-774.
11. Etienne MC, Lagrange JL, Dassonville O, et al. Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 1994; 12:2248-2253.
12. Lu Z, Zhang R, Carpenter JT, et al. Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: implication for 5-fluorouracil-based chemotherapy. Clin Cancer Res 1998; 4:325-329.
13. Johnson MR, Yan J, Shao L, et al. Semi-automated radioassay for determination of dihydropyrimidine dehydrogenase (DPD) activity. Screening cancer patients for DPD deficiency, a condition associated with 5-fluorouracil toxicity. J Chromatogr B Biomed Sci Appl 1997; 696:183-191.
14. Saif MW, Diasio RB. Is capecitabine safe in patients with gastrointestinal cancer and dihydropyrimidine dehydrogenase deficiency? Clin Colorectal Cancer 2006; 5:359-362.
15. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001; 19:2282-2292.
16. Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001; 19:4097-4106.
17. Mininberg ED, Johnson MR. Cisneros A, et al. Tolerance of capecitabine in a patient with partial dihydropyrimidine dehydrogenase (DPD) deficiency who experienced life-threatening toxicity to 5FU. Proc Am Soc Clin Oncol 2002; 21(pt 2 of 2):140b (Abstract #2375).
18. Head JE, Ring A. 25th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, USA, 10-14 December 2002: update on preclinical and translational research. Breast Cancer Res 2003; 5:109-112.
19. Lokich JJ, Moore C. Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome. Ann Intern Med 1984; 101:798-799.
20. Gordon KB, Tajuddin A, Guitart J, et al. Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy. Cancer 1995; 75:2169-2173.
21. Pagliuca A, Kaczmarski R, Mufti GJ. Palmar-plantar erythema associated with combination chemotherapy. Postgrad Med J 1990; 66:242-243.
22. Lin E, Morris JS, Ayers GD. Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. Oncology (Williston Park) 2002; 16(12 suppl 14):3l-37.
23. Doyle LA, Berg C, Bottino G, et al. Erythema and desquamation after high-dose methotrexate. Ann Intern Med 1983; 98(5 pt 1):611-612.
24. Vakalis D, Loannides D. Acral erythema induced by chemotherapy with cisplatin. Br J Dermatol 1998; 139:750.
25. Cleveland MG, Ajaikumar BS, Reganti R. Cutaneous fibrosis induced by docetaxel: a case report. Cancer 2000; 88:1073-1081.
26. Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer. Results of a large phase III study. J Clin Oncol 2001; 19:4097-4107.
27. Nita ME, Tominaga O, Nagawa H, et al. Dihydropyrimidine dehydrogenase but not thymidylate synthase expression is associated with resistance to 5-FU in colorectal cancer. Hepatogastroenterology 1998; 45:2117-2122.
28. Pazdur R, Lassere Y, Diaz-Canton E, et al. Phase I trial of uracil-tegafur (UFT) plus oral leucovorin: 14-day schedule. Invest New Drugs 1997; 15:123-128.
29. Hoff PM, Wenske CA, Medgyesy DC, et al. Phase I and pharmacokinetic study of the novel oral fluoropyrimidine, S-1. Proc Am Soc Clin Oncol 1999; 18:173a (Abstract #665).
30. Sakata Y, Ohtsu A, Horikoshi N, et al. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 1998; 34:1715-1720.
31. Elasmar SA, Saad ED, Hoff PM. Case report: hand-foot syndrome induced by the oral fluoropyrimidine S-1. Jpn J Clin Oncol 2001; 31:172-174.
32. Guo XD, Harold N, Saif MW, et al. Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule. Cancer Chemother Pharmacol 2003; 52:79-85.
33. van Kuilenburg AB. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluouracil. Eur J Cancer 2004; 40:939-950.
34. Marse H, Van Cutsem E, Grothey A, et al. Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda). Eur J Oncol Nurs 2004; 8(suppl 1):S16-S30.
35. Fabian CJ, Molina R, Slavik M, et al. Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. Invest New Drugs 1990; 8:57-63.
36. Brophy JM. Celecoxib and cardiovascular risks. Expert Opin Drug Saf 2005; 4:1005-1015.
37. Kingsley EC. 5-Fluorouracil dermatitis prophylaxis with a nicotine patch. Ann Intern Med 1994; 120:813.
38. El-Helw L, Coleman RE. Reduced dose capecitabine is an effective and well-tolerated treatment in patients with metastatic breast cancer. Breast 2005; 14:368-374.